Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
NCT06009653 · Washington University School of Medicine · PHASE4 · withdrawn · last registry update 2025-02-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was discontinued prematurely for administrative reasons” | – | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GIPR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-22Phase 3 first posted: Eli Lilly and Company, Retatrutide (NCT07357415)
- 2025-12-23Phase 3 first posted: University of Virginia, Tirzepatide (NCT07298915)
- 2025-12-16Phase 3 first posted: McGill University Health Centre/Research Institute of the McGill University Health Centre, Tirzepatide (NCT07284511)
- 2025-12-05Results posted on the registry: The Cleveland Clinic, GLP-1 medication (NCT06533527)
- 2025-11-26Results posted on the registry: Eli Lilly and Company, Tirzepatide + Semaglutide (NCT05822830)
- 2025-11-18Phase 3 first posted: Eli Lilly and Company, Retatrutide + Placebo (NCT07232719)
- 2025-10-31Phase 3 first posted: University of Texas Southwestern Medical Center, Weight loss (NCT07223242)
- 2025-10-21Results posted on the registry: Eli Lilly and Company, Tirzepatide + Placebo (NCT05963022)
- 2025-09-26Results posted on the registry: Eli Lilly and Company, Tirzepatide Dose 1 + Tirzepatide Dose 2 (NCT05260021)
- 2025-09-24Also stopped (withdrawn): Eli Lilly and Company, Bimagrumab + Tirzepatide (NCT06901349)
- 2025-09-10Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Retatrutide (NCT07165028)
- 2025-08-26Results posted on the registry: Eli Lilly and Company, Tirzepatide + Placebo (NCT05696847)
- 2025-08-20Results posted on the registry: Eli Lilly and Company, Tirzepatide (NCT04847557)
- 2025-08-08Results posted on the registry: Eli Lilly and Company, Tirzepatide + Placebo (NCT05691712)
- 2025-08-03Results posted on the registry: Eli Lilly and Company, Tirzepatide + Dulaglutide (NCT05564039)
- 2025-06-24Phase 3 first posted: Eli Lilly and Company, Retatrutide + Placebo (NCT07035093)
- 2025-05-08Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Placebo (NCT06962280)
- 2025-04-30Results posted on the registry: Eli Lilly and Company, Tirzepatide + Placebo (NCT05412004)
- 2025-04-27Results posted on the registry: Eli Lilly and Company, Tirzepatide (NCT05978713)
- 2025-04-22Phase 3 first posted: Eli Lilly and Company, Mirikizumab + Mirikizumab (NCT06937086)
- 2025-04-22Phase 3 first posted: Eli Lilly and Company, Mirikizumab + Mirikizumab (NCT06937099)
- 2025-04-09Phase 3 first posted: Chittagong Medical College, Tirzepatide (NCT06918405)
- 2025-04-06Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Placebo (NCT06914895)
- 2025-03-13Also stopped (terminated): BioAge Labs, Inc., Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) (NCT06515418)
- 2025-03-05Phase 3 first posted: Eli Lilly and Company, Retatrutide + Placebo (NCT06859268)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision